Amsterdam - Delayed Quote EUR

Galapagos NV (GLPG.AS)

22.72
+0.16
+(0.71%)
At close: May 9 at 5:37:02 PM GMT+2
Loading Chart for GLPG.AS
  • Previous Close 22.56
  • Open 22.42
  • Bid --
  • Ask --
  • Day's Range 22.42 - 22.90
  • 52 Week Range 20.00 - 31.08
  • Volume 113,600
  • Avg. Volume 115,158
  • Market Cap (intraday) 1.56B
  • Beta (5Y Monthly) -0.05
  • PE Ratio (TTM) --
  • EPS (TTM) -2.73
  • Earnings Date Jul 23, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 31.91

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

www.glpg.com

704

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GLPG.AS

View More

Performance Overview: GLPG.AS

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is AEX-Index (^AEX) .

YTD Return

GLPG.AS
14.33%
AEX-Index (^AEX)
3.09%

1-Year Return

GLPG.AS
15.29%
AEX-Index (^AEX)
0.17%

3-Year Return

GLPG.AS
58.75%
AEX-Index (^AEX)
35.96%

5-Year Return

GLPG.AS
88.72%
AEX-Index (^AEX)
73.99%

Compare To: GLPG.AS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GLPG.AS

View More

Valuation Measures

As of 5/9/2025
  • Market Cap

    1.50B

  • Enterprise Value

    -1.79B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.19

  • Price/Book (mrq)

    0.54

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -58.83%

  • Return on Assets (ttm)

    -4.66%

  • Return on Equity (ttm)

    -6.36%

  • Revenue (ttm)

    288.19M

  • Net Income Avi to Common (ttm)

    -179.34M

  • Diluted EPS (ttm)

    -2.73

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.3B

  • Total Debt/Equity (mrq)

    0.40%

  • Levered Free Cash Flow (ttm)

    -106.09M

Research Analysis: GLPG.AS

View More

People Also Watch